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ABSTRACT (249 words) 
Aims: To evaluate the relationship between expression of Myxovirus-resistance 
protein A (MxA) protein on muscle biopsies by immunohistochemistry and disease 
activity in JDM patients. Also, another aim was to investigate whether the expression 
of MxA is related with myositis-specific autoantibodies (MSA) status in JDM patients. 
Methods: 103 patients (median aged 6.3, IQR 0.5-15.9) enrolled in the Juvenile 
Dermatomyositis Cohort and Biomarker Study (JDCBS). Muscle biopsies were 
stained with MxA and scored. Clinical data at initial presentation were collected and 
autoantibodies were analysed. Multiple linear regression analysis was performed to 
estimate the association between MxA expression on muscle fibres and muscle 
disease activity, and MSA status.  
Results: Expression of MxA protein on JDM samples was identified in 61.2%. There 
was a significant association between MxA scores and Childhood Myositis 
Assessment Scale (CMAS) (p = 0.002), and Manual Muscle Testing of Eight Muscles 
(MMT8) (p = 0.026). CMAS and MMT8 scores were significantly lower in the group of 
patients with strong MxA expression. MxA scores differed according to MSA 
subgroups (p = 0.002). Patients with positive NXP-2 autoantibodies had strong MxA 
expression whereas anti-MDA5 positive patients had no or weak MxA expression. 
Conclusions: This study reveals the significant association between level of MxA 
expression on muscle fibres and clinical measures of muscular disease activity in 
JDM patients and MSA status. This confirms type I interferonopathies in muscle 
fibres of JDM patients which could help with improving treatment outcome in JDM 
patients and underscoring the distinct pathophysiological pathways in different MSA 
status.  
Keywords: Juvenile dermatomyositis, Myositis, Biopsy, Interferon, Marker, Disease 
activity, antibody, Myositis-specific autoantibody 
 
Abbreviations: 
β         Standardised coefficient  
CK   Creatine kinase 
CMAS   Childhood Myositis Assessment Scale 
DM   Dermatomyositis 
ELISA   Enzyme-linked immunosorbent assay 
hVAS   Histopathologists’ visual analogue score 
IFN   Interferon 
IHC   Immunohistochemistry 
IIM   Idiopathic inflammatory myopathies 
IQR   Interquartile range 
JDCBS  Juvenile Dermatomyositis Cohort and Biomarker Study 
JDM   Juvenile dermatomyositis 
L   Litre 
LDH   Lactate dehydrogenase 
MDA-5  Melanoma differentiation-associated gene 5 
MMT8   Manual Muscle Testing of Eight Muscles 
MSA   Myositis-specific autoantibodies 
MxA   Myxovirus-resistance protein A 
NXP-2  Nuclear matrix protein-2 
PGA   Physician’s global assessment 
TIF1ɣ   Transcriptional intermediary factor 1- gamma 
 
Introduction 
Juvenile dermatomyositis (JDM) is a rare chronic inflammatory myopathy of 
childhood, with primary symptoms including symmetrical, proximal muscle weakness 
and typical skin rashes including Gottron’s papules and heliotrope rash. Activated 
type I interferon (IFN) pathway has been shown to be a key factor in pathogenesis of 
JDM and adult dermatomyositis (DM) (1-3). Myxovirus-resistance protein A (MxA) 
which is one of the type I IFN induced proteins, and is specifically regulated by the 
type I IFN pathway (4, 5). During the last decade, type I IFN gene expression in 
blood has been shown to correlate with disease activity and muscle involvement in 
DM patients (6, 7). Also, MxA expression in muscle of DM patients has been 
previously demonstrated (2, 8). Moreover, a previous report has shown that the 
expression of type I IFN signature genes in muscle tissues of adult DM patients were 
stronger than in JDM patients except for MX1 gene (9). Since muscle is the major 
target of inflammation in JDM, the presence of MxA protein in muscle biopsies could 
of a relevance to direct mechanisms of tissue injury. This study aimed to evaluate 
the relationship between expression of MxA protein on muscle biopsies by 
immunohistochemistry and disease activity in JDM patients. Moreover, myositis-
specific autoantibodies (MSA) which are exclusively present in myositis patients, 
have been shown to help describe distinct groups of patients with similar clinical 
characteristics, treatment outcome and prognosis (10-15). A secondary aim of this 
study was to investigate whether the expression of MxA is related with MSA status in 
JDM patients. 
 
Materials and Methods 
Patients, clinical features and laboratory data. This study included clinical data 
and muscle biopsy samples from 103 patients with definite or probable JDM (16, 17)  
who were already recruited to the Juvenile Dermatomyositis Cohort and Biomarker 
Study (JDCBS) (18). Written informed consent and age appropriate assent were 
received from parents and patients respectively. The study was approved by the 
Northern & Yorkshire Medical Research and Ethics Committee (MREC), UK. Patient 
data were obtained through the JDCBS database including age at disease onset, 
gender, time between onset and biopsy date, and whether any medication was 
received before muscle biopsy. Clinical features at presentation were collected 
including the presence of calcinosis, nail fold capillary abnormality, pulmonary 
involvement, Childhood Myositis Assessment Scale (CMAS) (19), Manual Muscle 
Testing of Eight Muscles (MMT8) (20), and the physician’s global assessment 
(PGA). The CMAS has a range from 0 to 52, with high scores corresponding to no 
physical disability. The MMT8 ranges from 0 to 80, with high scores indicating no 
muscle weakness. The PGA is the assessment of the patient’s overall disease 
activity scored by a physician at the time of assessment, ranging from 0 to 10 (high 
scores corresponding to maximal disease). Serum levels of muscle enzymes 
including creatinine kinase (CK), lactate dehydrogenase (LDH), and aldolase were 
routinely collected at the first visit. 
Autoantibody detection. Autoantibodies were screened for by radio-
immunoprecipitation as described previously (21). Anti-nuclear matrix protein 2 (NXP-
2) and anti-melanoma differentiation-associated gene 5 (MDA5) antibodies were 
subsequently confirmed by enzyme-linked immunosorbent assay (ELISA) (11, 12). 
We included patients with MSA and no-detectable autoantibodies during the 
analyses in order to assess the relationships between MSA status and MxA 
expression on JDM muscle specimens.  
Muscle biopsy tissues and scoring data. Open biopsy material obtained from 
vastus lateralis of 103 patients were analysed. All muscle biopsy samples were 
snap-frozen within 1 hour of operation and stored at -80°C. Cryostat sections (7 µm) 
were cut, air-dried overnight, fixed with acetone, and stored at -80°C until used. All 
cases had been stained and scored according to a standardised scoring system as 
described (22, 23). The scoring tool consists of four domains: inflammatory, 
vascular, muscle fibre and connective tissue domain. Total biopsy score is the sum 
of all four domains (range 0-27; high scores indicate severe pathological 
abnormalities). This tool also includes a histopathologists’ Visual Analogue Score 
(hVAS) which assessed the overall severity (range 0-10; high scores indicate worse 
pathology). A set of normal muscle biopsies from subjects with no muscle disease 
were analysed in parallel for comparison (24). Biopsy scores and clinical and 
serology data for most of the patients reported in the present study overlap with 
those previously reported by our group (25). The MxA staining data have not yet 
been reported. 
Immunohistochemical (IHC) staining of MxA protein and microscopic 
evaluation. 103 patients had muscle biopsy tissues available which were manually 
stained for MxA by IHC staining. All specimens were also stained and scored using 
the standardised score tool for JDM histopathology previously reported to maintain 
consistency (22). The primary antibodies used to detect MxA protein were mouse 
anti-human anti-MxA monoclonal antibodies (clone: M143, 1:400 dilution, Merck, 
New Jersey, USA) Horseradish peroxidase and DAB (Dako, Cambridgeshire, UK) 
were used as secondary antibodies and the chromogen, respectively. Fiji imaging 
software was used to process the images. The expression of MxA in muscle fibres 
was scored semi-quantitatively by 2 independent investigators including a senior 
neurohistopathologist who were blinded to patients’ clinical features and laboratory 
data. The scores ranged from 0 to 3 (0 = no MxA staining; 1 = weak; 2 = moderate; 3 
= strong). In each specimen, the patterns of MxA staining were evaluated as either 
perifascicular, non-perifascicular or both. Perifascicular pattern was defined by the 
presence of brown staining at the peripheral area of muscle fibres and the definition 
of non-perifascicular pattern was patchy or diffuse staining in a section.  
Statistical analyses. Data were analysed using SPSS Statistics for Windows 
(Version 23.0. IBM Corporation). Descriptive statistics of baseline characteristics 
were summarised using median and interquartile range (IQR) for numeric variables 
and percentages for categorical variables. Differences in CMAS scores, MMT8, 
PGA, and serum levels of muscle enzymes between different MxA scoring data were 
tested by Kruskal-Wallis analysis of variance. Post hoc tests were performed to 
explore significant differences between pairs of MxA scoring data and p-values were 
adjusted by using Bonferroni’s correction for multiple comparisons. Fishers’ exact 
test was used to examine differences of MxA scoring data in different MSA 
subgroups. To estimate the association between the extent of MxA expression on 
muscle fibres and disease activity, multiple linear regression analysis was 
performed. The strength of the association from the regression analysis was 
described by the standardised coefficient (β). The inter-observer variability was 
analysed using Bland-Altman method which the mean difference (-0.05) and 95% 
limits of agreement (0.048, -0.148) were calculated and confirmed high agreement.  
P-values < 0.05 were considered statistically significant. 
 
Results 
Demographic data, clinical features and laboratory data  
Demographic data and clinical characteristics of all 103 JDM patients are 
summarised in Table 1. There was a female predominance (64.1%). Median age at 
disease onset was 6.3 (0.5-15.9) years and median duration from disease onset to 
muscle biopsy was 3.8 (2.6-8.7) months. Patients represented a range of disease 
severities. About 9% and 11% of patients had received corticosteroids and 
methotrexate at time of muscle biopsy, respectively. Since immunosuppressive 
drugs, such as corticosteroids and methotrexate, have been shown to have an effect 
on the type 1 IFN pathway (26), we compared patients who had received no drugs 
prior to biopsy to those who had received immunosuppressive drugs: there were no 
differences in clinical features, laboratory data and MxA scoring data between the 
two groups (Supplementary table 1). Thus, all 103 patients were included in the 
study. The three most prevalent MSA detected in these patients were anti-TIF1ɣ 
(19.8%), anti-NXP-2 (18.8%) and anti-MDA5 (11.9%) which was consistent with 
previous reports (10, 27). 
 
Expression of MxA protein in muscle fibres from JDM patients 
Representative immunohistochemical staining of MxA protein expression in muscle 
fibres from JDM patients are shown in Figure 1A. Expression of MxA protein on 
muscle fibres of JDM samples was identified in 63 patients (61.2%) (Figure 1B) 
whereas 82.5% of JDM patients had diffuse staining on capillaries. Moreover, in 
normal control muscle biopsies, about 67% had capillary staining of MxA while MxA 
protein was not expressed in all (data not shown). Among patients with positive MxA 
staining on muscle fibres, more than half of them (57.1%) had strong MxA 
expression. The distribution of MxA expression was observed in both perifascicular 
(46%) and non-perifascicular (53%) patterns.  
 
Increased MxA expression on muscle fibres was associated with increased muscular 
disease activity in JDM  
The distribution of different MxA scores did not differ according to age at disease 
onset, gender, or clinical features at first presentation, such as, the presence of 
calcinosis, nail fold capillary changes or PGA (Supplementary table 2). However, 
there was a significant association between MxA scores and CMAS, and MMT8 (p = 
0.002 and 0.026, respectively). The post hoc analysis showed the significant 
differences in CMAS score between patients with MxA scores of 0 and 2 (p = 0.044), 
and MxA scores of 0 and 3 (p = 0.001) (Figure 2A). The median CMAS score in the 
strong MxA expression group was 19 (9-46) whereas in the group with no MxA 
expression, the CMAS score was 41.5 (29-52). Similarly, MMT8 scores differed 
significantly between patients with MxA scores of 0 and 3 (p = 0.013) (Figure 2B). 
Since there was evidence of a significant association with time from disease onset to 
muscle biopsy (p = 0.046), multiple linear regression analysis was performed in order 
to confirm the associations between MxA scoring data and CMAS scores, and MMT8 
after adjustment for any confounding effects of time from disease onset to biopsy. 
From this analysis, expression of MxA protein was found to be significantly 
associated with CMAS scores and MMT8 at disease onset (Figure 2C, 2D). Thus 
patients with MxA scores of 3 had on the average 16 units lower scores CMAS 
scores when compared to patients with MxA scores of 0 and patients with MxA 
scores of 1 had on average 7 units lower CMAS scores when compared to patients 
with MxA scores of 0. Similarly, patients with MxA scores of 3 were associated with 
an average of 17 units lower MMT8 scores than patients with MxA scores of 0. 
Laboratory markers of disease severity, such as CK and LDH were also investigated 
for the relationship of MxA scoring data. However, serum levels of muscle enzymes 
were not associated with the expression of MxA protein on JDM muscle samples 
(Supplementary table 2). 
 
NXP-2 and MDA5 autoantibodies had differing levels of MxA expression on JDM 
muscle fibres 
The extent of MxA expression differed significantly according to MSA subgroups (p = 
0.002). Patients with positive NXP-2 autoantibodies tended to have strong MxA 
expression whereas anti-MDA5 positive patients had no or weak MxA expression on 
muscle biopsies (Figure 3). There was no clear trend in patients with other MSA 
subtypes or no-detectable autoantibodies. According to the distribution patterns of 
MxA staining, there was no clear association between different MSA subgroups and 
characteristic MxA stains in JDM muscle samples (p = 0.084, Supplementary table 
3). However, this borderline insignificant finding needs to be further investigated in a 
larger study. 
 
The expression of MxA protein on JDM muscle fibres was highly associated with 
scores of histopathological severity 
The levels of MxA expression on muscle samples had a positive correlation with 
several features of the biopsy scoring tool including the inflammatory domain and 
muscle fibre domains, total biopsy scores and histopathologist’s visual analogue 
score (hVAS) (Figure 4A-D). There were significantly statistical differences in those 
biopsy domains between patients with MxA score of 0 and 3. Interestingly, patients 
with MxA scores of 0 and 1 tended to have wider range of scores in inflammatory 
domain, and total biopsy score when compared to patients with MxA scores of 2 and 
3. 
 
Discussion 
To our knowledge, this is the first study to demonstrate MxA protein 
expression on muscle fibres in a large cohort of JDM muscle biopsies (n=103). 
Assessment muscle biopsies from JDM patients has the potential to reveal 
pathophysiology of JDM. The expression of MxA protein on muscle biopsies 
detected by immunohistochemical staining has been recently demonstrated and a 
role as a marker for diagnosis of dermatomyositis suggested, in a study of 34 cases 
of DM (of which 10 were JDM patients) (28). Although the sample size in the 
previous study was limited, there was about 90% of JDM patients who had positive 
MxA staining in muscle fibres. The percentages of positive MxA staining in JDM in 
the previous study is higher than in this study which was about 61% could be 
explained by the different classification criteria for including of participants and 
different MxA clones for immunohistochemistry detection. Further possible 
explanations would be the differences in median age at disease onset, duration from 
disease onset to muscle biopsy and the location of muscle the biopsy was taken 
from. However, these details were not provided in the previous study. Building upon 
this, our study has demonstrated that MxA expression may also be used as a 
histological biomarker for JDM disease activity within the muscle tissue. We revealed 
the strong association between type I IFN response in muscle tissues as assessed 
by immunohistochemical staining of MxA protein and muscle disease activity in JDM 
patients. In patients with high degree of muscle disease severity, MxA protein 
expression on muscle fibres was found at elevated levels. However, no association 
was identified between degree of MxA expression on muscle tissue and serum levels 
of muscle enzymes CK and LDH. These data support that serum levels of muscle 
enzymes do not correlate well with JDM disease activity as previously reported (29, 
30). Previous studies have used gene expression profiling to demonstrate correlation 
between type I IFN response in blood and muscle disease activity in adult DM and 
JDM (6, 7, 26, 31). Muscle from adult DM patients showed significant higher levels of 
MxA expression than in blood (26). This was explained by the hypothesis that some 
infiltrating inflammatory cells in muscle tissues themselves can express MxA. 
However, in our study, we measured degrees of MxA protein expression only in 
muscle fibres, not in inflammatory cells. 
Additionally, this is the first study revealing the association of level of MxA 
protein expression on muscle fibres and MSA subtype specificities in JDM patients. 
There are few studies showing the correlation between specificities of myositis 
autoantibodies and IFN pathway activation in blood. A previous study in adult 
patients showed a significantly higher whole blood IFN score in patients with 
idiopathic inflammatory myopathies (IIM) who had anti-Jo1, anti-Ro60 and anti-
U1RNP autoantibodies when compared to patients with positive anti-Ro52 and anti-
PM/Scl (32). However, no data demonstrates the association between other major 
MSA and levels of IFN pathway activation in JDM patients. Moreover, there are 
limited studies describing characteristics of muscle histopathology and degrees of 
muscular inflammation in distinct MSA subtypes. A recent study showed that anti-
NXP-2 JDM cases had variable scores of histopathological severity (25) whereas a 
study of adult DM demonstrated that anti-NXP-2 patients had less muscle 
inflammation (33). In the present study, we observed that patients with NXP-2 
autoantibodies had greater degree of muscle inflammation since they had higher 
level of MxA expression on muscle fibres than other MSA subgroups. In contrast, 
there was no or low levels of MxA protein expression on muscle biopsies in patients 
with anti-MDA5 autoantibodies. Previous studies also showed that anti-MDA5 
antibodies were associated with milder muscle disease activity and muscle 
pathology than patients with other MSA subgroups (12, 25). Also, adult patients with 
anti-MDA5 autoantibodies did not have perifascicular atrophy which is one of the 
classic pathological features of DM (34) whereas about 58.3% of anti-MDA5 positive 
patients in this study had perifascicular atrophy. This could be due to the different 
pathological findings between adult and paediatric patients. Moreover, a previous 
Japanese study showed that among muscle biopsies from 3 patients with anti-MDA5 
autoantibodies, none of the patients had perifascicular atrophy and 2 patients had 
MxA expression on muscle fibres (28). In this study, although sample size in this 
MSA subgroup was limited, about 33.3% of anti-MDA5 autoantibodies positive 
patients demonstrated expression of MxA protein on muscle fibres. Another 
Japanese study demonstrated that anti-MDA5 autoantibody positive DM patients had 
higher levels of serum IFN-α than in those negative for anti-MDA5 autoantibodies 
(35). These variable results may reflect genetic and environmental differences 
between anti-MDA5 positive patients. It is known that the MDA5 positive patients 
typically have mild muscle disease and it is therefore possible that interferon 
inducible proteins mainly circulate in blood but are not highly expressed in muscles 
of patients with MDA5 autoantibodies. Moreover, some evidence suggests a 
possible protective mechanism through nitric oxide synthase 2 expression in skeletal 
muscle of anti-MDA5 autoantibody positive patients (34). Thus, MDA5 positive 
patients have limited muscular involvement while they have more severe extra 
muscular manifestations, such as pulmonary involvement. These results confirm the 
divergent disease pathophysiology of JDM in different MSA positive groups. Our 
study showed strong correlations between the degree of MxA expression on muscle 
fibres and several domains in the JDM biopsy scoring tool (22). Interestingly, the 
distribution of scores in inflammatory domain and total biopsy scores in patients with 
no or weak MxA expression tended to have wider range of scores. This may suggest 
that muscle biopsy specimens with high MxA protein expression might provide more 
convincing information of muscle tissue injury.  
In summary, in this study, we identified MxA protein expression in muscle 
fibres as a useful histological biomarker of JDM disease activity to supplement the 
assessment IFN pathway activation and management of JDM patients. This could 
help with improving treatment outcome and minimizing comorbidities associated with 
treatment and disease in JDM patients. Moreover, we emphasise the association of 
different MSA subgroups in stimulation of the IFN type I pathway which involved in 
muscle damage in JDM and underscore the distinct pathophysiological pathways in 
different MSA status. This needs the careful phenotyping of JDM patients for tailored 
therapy for better outcome. 
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Table 1. Demographic data and clinical features of 103 JDM patients at initial 
presentation 
Characteristics Median (IQR)* 
Female, n (%) 66 (64.1%) 
Age at disease onset, years 6.3 (0.5-15.9) 
Duration from disease onset to first visit, months  4.3 (2.7-9.8) 
Time from disease onset to muscle biopsy, months 3.8 (2.6-8.7) 
Time from first visit to muscle biopsy, months 0.67 (0.35-0.86) 
On immunosuppressive drugs at time of biopsy, n (%) 
- Corticosteroids 
- Methotrexate 
 
9 (8.7) 
11 (10.7) 
CMAS (n=90) 28.5 (16-45) 
MMT8 (n=62) 54 (35-71) 
PGA (n=72) 5.95 (3.5-7.7) 
CK, units/L (n=96) 367 (77-2146.5) 
Myositis specific autoantibodies, n (%) (n=75) 
- MDA5 
- NXP-2 
- Mi2 
- TIF1g 
- No detectable 
 
12 (11.9) 
19 (18.8) 
5 (5) 
20 (19.8) 
19 (18.8) 
*Data are presented as median [IQR (interquartile range)] if not stated otherwise. 
CK, Creatinine kinase; CMAS, Childhood Myositis Assessment Scale (scores 0-52); 
MDA5, melanoma differentiation-associated gene 5; MMT8, Manual Muscle Testing 
of Eight Muscles (scores 0-80); NXP-2, nuclear matrix protein; PGA, physician global 
assessment (scores 0-10); TIF1g, transcriptional intermediary factor 1-gamma. 
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Figure 1. Immunohistochemical staining of Myxovirus-resistance protein A 
(MxA) in juvenile dermatomyositis (JDM) muscle tissues. (A) Representative 
immunohistochemical staining of MxA in JDM biopsies. (a1) Negative MxA staining in 
muscle fibres. (a2) Perifascicular MxA expression with score of 1. (a3) Non-
perifascicular MxA expression with score of 1. (a4) Non-perifascicular and 
perifascicular MxA expression with score of 2. (a5) Perifascicular MxA expression 
with score of 2. (a6) Strong non-perifascicular MxA expression with score of 3. 
Original magnifications: x20 (a1); x10 (a2-6). (B) Percentage of patients in different 
degrees of MxA expression in 103 JDM patients. MxA total score was analysed in a 
whole image of specimens. In each specimen, the patterns of MxA staining were 
evaluated as either perifascicular, non-perifascicular or both. 
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Figure 2. Association between muscular disease activity and relative MxA 
protein expression on JDM muscle samples. Distribution of (A) CMAS score (p = 
0.002), (B) MMT8 (p = 0.026) across MxA scoring data. Kruskal-Wallis ANOVA was 
tested to analyse the difference in the distribution. Horizontal bars show median 
values. Post-hoc comparisons were automatically performed when the p-value was 
statistically significant.  Forest plots of linear regression-estimated coefficients for (C) 
CMAS and (D) MMT8 showing significant relationships between MxA protein 
expression on JDM muscles and muscular disease activity. CMAS, Childhood 
Myositis Assessment Scale; JDM, juvenile dermatomyositis; MMT8, Manual Muscle 
Testing of Eight Muscles; MxA, myxovirus resistance protein A. 
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Figure 3. Distributions of MxA protein expression on JDM muscle samples 
across MSA subgroups. Fishers’ exact test was done to analyse the difference in 
the distributions and p-value was 0.002. JDM, juvenile dermatomyositis; MDA5, 
melanoma differentiation-associated gene 5; MSA, myositis-specific autoantibody; 
MxA, myxovirus resistance protein A; NXP-2, nuclear matrix protein; TIF1g, 
transcriptional intermediary factor 1-gamma. 
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Figure 4. Relationships between MxA scoring data and different domains in a 
biopsy scoring tool, and IFN gene expression. Distribution of scores in (A) 
inflammatory domain (p-value from Kruskal-Wallis ANOVA was 0.001), (B) muscle 
fibre domain (p-value was 0.014), in a biopsy scoring tool, (C) total biopsy score (p-
value was 0.002), (D) hVAS (p-value was 0.004) in different MxA protein expression 
on JDM muscle samples. Horizontal bars show median values. Post-hoc 
comparisons were automatically performed when the p-value from Kruskal-Wallis 
ANOVA was statistically significant. ANOVA, analysis of variance; hVAS, 
histopathologist’s visual analogue scale global pathology score; IFN, interferon; 
JDM, juvenile dermatomyositis; MxA, myxovirus resistance protein A. 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary data 
Supplementary Table 1. Clinical features and laboratory data at initial 
presentation between JDM patients who had received corticosteroid and/or 
methotrexate and those who had no drugs prior to muscle biopsy  
Characteristics Patients not on 
drugs at time of 
biopsy (n=92), 
median (IQR)* 
Patients on drugs 
at time of biopsy 
(n=11), median 
(IQR)* 
P-value 
Female, n (%) 59 (64.1%) 7 (63.6%) 0.796 
Age at disease onset, 
years 
5.8 (3.8-9.2) 6.7 (2.6-7.7) 0.905 
CMAS (n=90) 27 (14.5-45.5) 32 (25.5-43.5) 0.365 
MMT8 (n=62) 54 (33-70.5) 63 (45.5-69) 0.563 
PGA (n=72) 6.2 (3.6-7.9) 4.5 (2.9-6.4) 0.270 
CK, units/L (n=96) 359 (75-3381) 375 (110.5-745.5) 0.617 
hVAS 5 (3-7.8) 4 (1.5-6) 0.203 
Total biopsy scores 16 (11-21) 14 (10-21) 0.516 
MxA scores 1 (0-3) 0 (0-2.5) 0.349 
 
*Data are presented as median [IQR (interquartile range)] if not stated otherwise. 
CK, Creatinine kinase; CMAS, Childhood Myositis Assessment Scale (scores 0-52); hVAS, 
histopathologist’s visual analogue scale global pathology score; JDM, juvenile 
dermatomyositis; MMT8, Manual Muscle Testing of Eight Muscles (scores 0-80); MxA, 
myxovirus resistance protein A; PGA, physician global assessment (scores 0-10). 
Supplementary Table 2. Characteristics and laboratory data at initial 
presentation of 103 JDM patients in different MxA scoring data 
Variables* MxA scores P-value 
0 1 2 3 
Female, n (%) 26 (25.2) 9 (8.7) 9 (8.7) 22 (21.4) 0.823 
Age at onset, 
years  
8.1 (3.5-
9.9) 
6.7 (4.5-
10.3) 
5.1 (3.7-
8.9) 
4.9 (3.5-
7.1) 
0.197 
Time onset to 
biopsy, months 
5.52 (3.36-
18.84) 
3.24 (2.4-
4.32) 
4.08 (2.16-
7.08) 
3.48 (2.04-
8.52) 
0.046 
Nail fold 
changes, n (%) 
(n=84) 
23 (27.4) 6 (7.1) 7 (8.3) 26 (30.9)  0.200 
Calcinosis, n (%) 
(n=83) 
4 (4.8) 1 (1.2) 0 2 (2.4) 0.091 
CMAS (n=90) 41.5 (29-
52) 
29 (24.5- 
39) 
22 (15-26) 19 (9-46) 0.002 
MMT8 (n=62) 68 (54-76) 40 (32.5-
55.5) 
44.5 (32-
78) 
41.5 (29-
63) 
0.026 
PGA (n=72) 4.7 (1.7-7) 3.6 (3-8) 7 (3.7-7.6) 7 (5-7.9) 0.189 
CK, units/L 
(n=96) 
148 (54-
1165) 
98 (71-
301.5) 
529 (341-
2510.5) 
446 (127-
3702) 
0.073 
 
*Data are presented as median [IQR (interquartile range)] if not stated otherwise. 
CK, Creatinine kinase; CMAS, Childhood Myositis Assessment Scale (scores 0-52); 
MMT8, Manual Muscle Testing of Eight Muscle (scores 0-80); MxA, myxovirus 
resistance protein A; PGA, physician global assessment (scores 0-10). 
 
Supplementary Table 3. Distributions of patterns of MxA staining on JDM 
muscle samples across MSA subgroups*. 
 
MSA status 
Patterns of MxA staining, n (%) 
Perifascicular Non-
perifascicular 
Both patterns Negative 
staining 
MDA5 (n=12) 0 (0%) 2 (16.7%) 2 (16.7%) 8 (66.7%) 
NXP-2 (n=19) 6 (31.6%) 3 (15.8%) 7 (36.8%) 3 (15.8%) 
Mi2 (n=5) 0 (0%) 2 (40%) 3 (60%) 0 (0%) 
TIF1g (n=20) 5 (25%) 3 (15%) 7 (35%) 5 (25%) 
No detectable 
(n=19) 
2 (10.5%) 2 (10.5%) 8 (42.1%) 7 (36.8%) 
 
*Fishers’ exact test was done to analyse the difference in the distributions and p-
value was 0.084. JDM, juvenile dermatomyositis; MDA5, melanoma differentiation-
associated gene 5; MSA, myositis-specific autoantibody; MxA, myxovirus resistance 
protein A; NXP-2, nuclear matrix protein; TIF1g, transcriptional intermediary factor 1-
gamma. 
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